The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[molybdate co-treated with INS1 protein] results in increased phosphorylation of INSR protein; [molybdate co-treated with INS1 protein] results in increased phosphorylation of IRS4 protein; [molybdate co-treated with Vanadates co-treated with INS1 protein] results in increased phosphorylation of INSR protein; molybdate promotes the reaction [[Vanadates co-treated with INS1 protein] results in increased phosphorylation of IRS4 protein]; Vanadates promotes the reaction [[molybdate co-treated with INS1 protein] results in increased phosphorylation of IRS4 protein]
[molybdate co-treated with INS1 protein] results in increased phosphorylation of INSR protein; [molybdate co-treated with Vanadates co-treated with INS1 protein] results in increased phosphorylation of INSR protein
[molybdate co-treated with INS1 protein] results in increased phosphorylation of IRS4 protein; molybdate promotes the reaction [[Vanadates co-treated with INS1 protein] results in increased phosphorylation of IRS4 protein]; Vanadates promotes the reaction [[molybdate co-treated with INS1 protein] results in increased phosphorylation of IRS4 protein]
molybdenum trioxide results in decreased activity of CAT protein chromous chloride affects the reaction [molybdenum trioxide results in decreased activity of CAT protein]; molybdenum trioxide affects the reaction [chromous chloride results in decreased activity of CAT protein]
sodium molybdate(VI) promotes the reaction [Tetrachlorodibenzodioxin binds to AHR protein] sodium molybdate(VI) inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein] sodium molybdate(VI) results in increased activity of AHR protein
[tetrathiomolybdate binds to APP 5' UTR] which results in decreased expression of APP protein; [tetrathiomolybdate binds to APP 5' UTR] which results in decreased secretion of APP protein modified form
tetrathiomolybdate inhibits the reaction [ATP7B gene mutant form results in increased abundance of Copper] tetrathiomolybdate results in decreased expression of ATP7B protein
tetrathiomolybdate analog results in increased expression of BCL2 mRNA; tetrathiomolybdate analog results in increased expression of BCL2 protein tetrathiomolybdate results in decreased expression of BCL2 protein
[Copper deficiency co-treated with tetrathiomolybdate] results in increased cleavage of BCL2L11 protein; [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of BCL2L11 protein
[Copper deficiency co-treated with tetrathiomolybdate] results in increased cleavage of CASP3 protein; [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of CASP3 protein tetrathiomolybdate results in increased cleavage of CASP3 protein
[Copper deficiency co-treated with tetrathiomolybdate] results in increased cleavage of CASP8 protein; [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of CASP8 protein
tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of CCL2 mRNA]; tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of CCL2 protein]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of and results in increased expression of CCL2 protein] tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of CCL2 mRNA]; tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of CCL2 protein]
tetrathiomolybdate results in decreased activity of CP protein tetrathiomolybdate results in decreased expression of CP protein tetrathiomolybdate results in decreased secretion of CP protein tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of CP protein]
[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; tetrathiomolybdate inhibits the reaction [EGF protein results in increased oxidation of PTPN1 protein]; tetrathiomolybdate inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]
tetrathiomolybdate inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] tetrathiomolybdate results in decreased expression of EGFR protein
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of ELN mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of ELN protein
[Copper deficiency co-treated with tetrathiomolybdate] inhibits the reaction [EP300 protein binds to HIF1A protein]; [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of EP300 protein
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of FBLN1 mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of FBLN1 protein
[Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of FBLN5 mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of FBLN5 protein
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of FBN1 mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of FBN1 protein
[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]; Vanadates inhibits the reaction [tetrathiomolybdate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]; Vanadates inhibits the reaction [tetrathiomolybdate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]
[Copper deficiency co-treated with tetrathiomolybdate] inhibits the reaction [EP300 protein binds to HIF1A protein]; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of HIF1A protein
tetrathiomolybdate results in decreased expression of HMOX1 protein tetrathiomolybdate analog results in increased expression of HMOX1 mRNA; tetrathiomolybdate analog results in increased expression of HMOX1 protein [tetrathiomolybdate analog results in increased abundance of Superoxides] which results in increased reduction of HMOX1 protein; Acetylcysteine inhibits the reaction [tetrathiomolybdate analog results in increased expression of HMOX1 protein]; Copper inhibits the reaction [tetrathiomolybdate analog results in increased expression of HMOX1 protein]
tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of ICAM1 mRNA]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of and results in increased expression of ICAM1 protein] tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of ICAM1 mRNA]; tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of ICAM1 protein]
[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK3 protein]; tetrathiomolybdate inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]
tetrathiomolybdate analog results in decreased expression of IL2RA mRNA tetrathiomolybdate inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]]
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of LOX mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of LOX protein
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased phosphorylation of MAPK1 protein tetrathiomolybdate results in decreased phosphorylation of MAPK1 protein [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK1 protein]; Hydrogen Peroxide inhibits the reaction [tetrathiomolybdate results in decreased phosphorylation of MAPK1 protein]; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]; Vanadates inhibits the reaction [tetrathiomolybdate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]] tetrathiomolybdate analog results in increased phosphorylation of MAPK1 protein
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased phosphorylation of MAPK3 protein tetrathiomolybdate results in decreased phosphorylation of MAPK3 protein tetrathiomolybdate analog results in increased phosphorylation of MAPK3 protein [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK3 protein]; Hydrogen Peroxide inhibits the reaction [tetrathiomolybdate results in decreased phosphorylation of MAPK3 protein]; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]; Vanadates inhibits the reaction [tetrathiomolybdate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]
[tetrathiomolybdate results in increased expression of SLC31A1 mRNA] which results in decreased susceptibility to oxaliplatin; [tetrathiomolybdate results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Carboplatin; [tetrathiomolybdate results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Cisplatin; tetrathiomolybdate promotes the reaction [SP1 protein binds to SLC31A1 promoter] tetrathiomolybdate results in decreased expression of SLC31A1 protein
tetrathiomolybdate results in decreased expression of SOD1 protein tetrathiomolybdate analog affects the localization of SOD1 protein tetrathiomolybdate results in decreased activity of SOD1 protein [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK1 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK3 protein]; [tetrathiomolybdate results in decreased activity of SOD1 protein] which results in decreased abundance of Hydrogen Peroxide; [tetrathiomolybdate results in decreased activity of SOD1 protein] which results in increased abundance of Superoxides; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]; Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]] tetrathiomolybdate analog results in decreased expression of SOD1 mRNA
[tetrathiomolybdate results in decreased abundance of Copper] which results in increased expression of SP1 protein; tetrathiomolybdate promotes the reaction [SP1 protein binds to SLC31A1 promoter]; tetrathiomolybdate promotes the reaction [SP1 protein binds to SP1 promoter] tetrathiomolybdate results in increased expression of SP1; tetrathiomolybdate results in increased expression of SP1 mRNA tetrathiomolybdate results in increased activity of SP1 protein
tetrathiomolybdate inhibits the reaction [Bleomycin results in increased expression of TNF mRNA]; tetrathiomolybdate inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF mRNA]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]
[Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of TP53 protein tetrathiomolybdate results in increased phosphorylation of TP53 protein
tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of VCAM1 mRNA]; tetrathiomolybdate inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of and results in increased expression of VCAM1 protein] tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of VCAM1 mRNA]; tetrathiomolybdate inhibits the reaction [Copper Sulfate results in increased expression of VCAM1 protein]
[Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of VEGFA mRNA; [Copper deficiency co-treated with tetrathiomolybdate] results in decreased expression of VEGFA protein tetrathiomolybdate results in decreased expression of VEGFA protein
browse the term
